Physician profile
Alexandra Smart
NPI 1184770869
$3,386.01
in general payments reported to CMS, 2019-2025
16 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 82% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $54.35 · 2021: $262 · 2022: $42.25 · 2023: $468 · 2024: $543 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,368.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,055.15 | 2019-2025 | Impella |
| Medtronic, INC. | $318.30 | 2024 | Corevalve Evolut R, Micra |
| Bayer Healthcare Pharmaceuticals INC. | $230.45 | 2019-2025 | |
| Inari Medical, INC. | $204.50 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $113.19 | 2024-2025 | Winrevair |
| United Therapeutics Corporation | $99.71 | 2019-2024 | Tyvaso |
| Abbott Laboratories | $77.99 | 2024 | Ensite Precision |
| Astrazeneca Pharmaceuticals LP | $60.16 | 2023-2025 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.42 | 2019-2024 | Ofev |
| Grifols USA, LLC | $37.60 | 2019-2021 | |
| Boston Scientific Corporation | $37.45 | 2021 | |
| Mylan Specialty L.P. | $30.95 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $24.87 | 2024 | Opsumit |
| Glaxosmithkline, LLC. | $17.33 | 2023 | Nucala |
| Novartis Pharmaceuticals Corporation | $16.48 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.